Drugs / SGT-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07148089 | Feb 2026 → Jun 2027 expected | catecholaminergic polymorphic ventricular tachycardia | Solid Biosciences Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-07-23 | Solid Biosciences Inc. | Regulatory Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) solidbio.com ↗
SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations |
| 2025-07-08 | Solid Biosciences Inc. | Regulatory Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) solidbio.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGT-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07148089 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) infusion (dose 1) of SGT-501.” NCT07148089 ↗ |